APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer
Key facts
- Who runs it
- Azienda Ospedaliero-Universitaria Careggi
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 180 people, planned
- Started
- 11 Mar 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SBRT on all sites of metastatic disease+Apalutamide
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients who have signed written informed consent
- Adult patients ≥ 18 years
- Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions *, **
- All lesions must be amenable to SBRT in judgment of treating radiation oncologist ***
- Patients with metastatic recurrence after previous radical prostatectomy or definitive radiotherapy will be included in the trial, provided that radical approach on prostate is administered
- Androgen deprivation therapy (ADT) started ≤ 6 months before enrollment
- Patients should be eligible to Apalutamide treatment
Who cannot take part
- Presence of visceral disease
- De novo metastatic disease
- Any condition for which, in the opinion of the treating physician, SBRT should not be proposed or could be contraindicated
- Any contraindication to the use of Apalutamide
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone. However, stereotactic body radiotherapy (SBRT) showed to improve outcomes of oligometastatic patients if compared to systemic therapy alone within modern randomized trial, including a mixed cohort of different pathologies. However, there are no trials specifically exploring the benefit offered by SBRT in oligometastatic mHSPC treated with Apalutamide if compared to Apalutamide alone associated to Androgen deprivation therapy. Thus, a randomized trial was designed to test specifically the hypotesis that SBRT will improve outcome in a selected population of oligometastatic mHSPC treated with Apalutamide and ADT, undergoing baseline staging according to local reimbursability.
The 2 groups in the trial
- ControlExisting treatment, for comparison
Androgen Deprivation therapy and Apalutamide
Treatment: SBRT on all sites of metastatic disease+Apalutamide
- TreatmentTreatment being tested
Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease
Treatment: SBRT on all sites of metastatic disease+Apalutamide
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN
- Record updated
- 17 November 2026